Dennis R. Di Ricco; Golden Genesis, INC. d/b/a Nuplasma; Thomas F. Casey v. Missouri Commissioner of Securities

CourtMissouri Court of Appeals
DecidedJuly 9, 2024
DocketWD86327
StatusPublished

This text of Dennis R. Di Ricco; Golden Genesis, INC. d/b/a Nuplasma; Thomas F. Casey v. Missouri Commissioner of Securities (Dennis R. Di Ricco; Golden Genesis, INC. d/b/a Nuplasma; Thomas F. Casey v. Missouri Commissioner of Securities) is published on Counsel Stack Legal Research, covering Missouri Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dennis R. Di Ricco; Golden Genesis, INC. d/b/a Nuplasma; Thomas F. Casey v. Missouri Commissioner of Securities, (Mo. Ct. App. 2024).

Opinion

IN THE MISSOURI COURT OF APPEALS WESTERN DISTRICT DENNIS R. DI RICCO, et al., ) ) Appellants, ) ) v. ) WD86327 ) (consolidated with WD86329 MISSOURI COMMISSIONER OF ) and WD86330) SECURITIES, et al., ) ) Filed: July 9, 2024 Respondents. ) Appeal from the Circuit Court of Cole County The Honorable Jon E. Beetem, Judge

Before Division One: Lisa White Hardwick, P.J., and Alok Ahuja and Anthony Rex Gabbert, JJ. The Missouri Commissioner of Securities found Golden Genesis, Inc.,

Thomas Casey, and Dennis Di Ricco liable for violations of the Missouri

Securities Act of 2003, §§ 409.1-101 to 409.7-703.1 The circuit court upheld the

Commissioner’s order. Golden Genesis, Casey, and Di Ricco appeal. They argue that the Commissioner lacked personal jurisdiction over them. The appellants

also argue that the promissory notes which investors executed did not constitute

“securities” subject to the Commissioner’s regulatory jurisdiction. We hold that the Comissioner lacked personal jurisdiction over Di Ricco, and accordingly

1 Statutory citations refer to the 2016 edition of the Revised Statutes of Missouri, updated through the 2023 Cumulative Supplement. reverse the Commissioner’s order as to him. The order is affirmed with respect to Golden Genesis and Casey.

Factual Background Golden Genesis was formed in March 2016 and incorporated in the State of Nevada. Golden Genesis was a start-up company whose objective was to develop

plasma donation centers in Texas under the name “NuPlasma.” Golden Genesis

contemplated that the NuPlasma centers would collect plasma samples from

young adult donors, for use in the treatment of age-related illnesses like

Parkinson’s and Alzheimer’s diseases.

This proceeding concerns loans extended to Golden Genesis by Missouri residents between May 2016 and January 2019. During the relevant period,

Casey was Golden Genesis’s majority shareholder, its Chief Executive Officer,

Chairman of its Board of Directors, and a signatory on all of Golden Genesis’s

bank accounts. Casey is domiciled in California.

Dennis Di Ricco began as Golden Genesis’s Chief Financial Officer on

March 31, 2016; he formally resigned this role in April 2016. However, during

the relevant period, Di Ricco remained Golden Genesis’s Corporate Secretary,

was a member of its Board, and was also a shareholder. Like Casey, Di Ricco was

a signatory on Golden Genesis’s bank accounts throughout the relevant period. Di Ricco is domiciled in the State of Washington.

In approximately March 2016, Di Ricco introduced Casey and Golden

Genesis to Retire Happy, LLC, a Nevada business. Retire Happy secured funding for start-up companies by finding individuals interested in investing funds from

their retirement accounts in “alternative investments.” During the relevant time,

2 Retire Happy was operated by Julie Minuskin, its sole managing member and Chief Executive Officer. Minuskin, a Nevada resident, was also a shareholder of

Golden Genesis between May 2016 and January 2019.

In April 2016, Golden Genesis entered into a one-page Consulting Agreement with Retire Happy. The Consulting Agreement stated in relevant

part:

1. Services. [Golden Genesis] hereby authorizes [Retire Happy], on a non-exclusive basis, to identify potential Investors interested in investing in [Golden Genesis’s] Promissory Note. [Retire Happy] agrees to identify Six Million Dollars ($6,000,000.00) for [Golden Genesis] within 12 months. 2. Investor. The investors which [Retire Happy] will introduce to [Golden Genesis] will be named and listed by signed copies of the Promissory Note provided by [Golden Genesis].

3. Initial Investment. Should an Investor invest in [Golden Genesis’s] Promissory Note, then [Golden Genesis] agrees to pay [Retire Happy] twelve percent (12%) of the proceeds invested in [Golden Genesis].

4. Consultant’s fees shall be based upon the gross amount invested, prior to any deductions, expenses or offsets of any kind. Payment will be made by cashier’s checks or bank wire payable to the order of [Retire Happy] by the Friday of the week of [Golden Genesis’s] receipt of the funds. 5. Limitation of Services. This agreement relates solely to [Retire Happy’s] services as a finder in introducing [Golden Genesis] to prospective investors. There are no additional services that [Retire Happy] is required to perform to be entitled to the above compensation in the event an investment is made. [RETIRE HAPPY] REPRESENTS THAT IT IS NOT A LICENSED SECURITIES DEALER, AND THAT THIS AGREEMENT IS NOT INTENDED FOR THE PURPOSE OF BUYING, Selling OR TRADING SECURITIES.

3 Retire Happy provided Golden Genesis and Casey a template promissory note (the “Note”) and informed Casey that the language of the document was not

to be modified in any fashion; Casey could only select the interval at which the

interest on the Notes would be calculated by placing a checkmark next to the appropriate selection.

Retire Happy and Casey developed a ten-page presentation

(“Presentation”) that Retire Happy later used while making sales pitches to

prospective investors. The Presentation claimed that “[p]lasma infusions from

young donors have just recently been proven to dramatically repair skeletal,

vascular, muscular, major organ and cognitive deterioration associated with aging,” and stated that Golden Genesis was “seeking $6 million in financing to

develop 6 plasmapheresis centers that will collect blood plasma from donors

between the ages of 18 and 25.” The Presentation proposed that investors would

invest funds in Golden Genesis by providing it with two-year loans, which would

earn ten percent simple interest, to be paid at the end of every month. The

Presentation stated that

Notes [would be] secured by a promissory note and a UCC-1 Financing Statement on all assets of Golden Genesis, Inc., including equipment, inventory (together with a rolling, multi-million dollar, 60 – 90 day supply of plasma at each operational facility), receivables, intellectual property, patents, and bank accounts. Copies of the UCC-1 will be sent to the lenders once filed. The Presentation clearly contemplated that the $6 million in funding which Golden Genesis was seeking would come from multiple, small investors. Thus,

the Presentation stated that “[f]unding will be in different amounts and at

different dates. Each loan is due two years from the date received by Golden

4 Genesis, Inc. (GG).” Moreover, the Presentation including a table indicating that investors would be entitled to purchase twelve units of Golden Genesis’ plasma at

wholesale rates. The table indicated that investors would become eligible for

discounts on the wholesale price of plasma, based on the magnitude of their investment. The discounts were tiered in $20,000 increments: thus, an investor

lending Golden Genesis between $20,000 and $40,000 would receive a ten

percent discount, while an investor investing “$100,000+” would receive a fifty

percent discount. The “$100,000+” category was the highest financing

increment contemplated in the Presentation.

Provident Trust Group, LLC, is a Nevada business providing custodial and administrative services for self-directed retirement accounts. Golden Genesis’s

promissory notes were issued exclusively to individuals who had accounts with

Provident.

Retire Happy purchased a list of investor leads from a third party, and

began contacting leads by telephone and e-mail on behalf of Golden Genesis. In

these communications, Retire Happy’s staff promoted self-directed Individual

Retirement Accounts and 401(k) accounts held by Provident.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Shaffer v. Heitner
433 U.S. 186 (Supreme Court, 1977)
Keeton v. Hustler Magazine, Inc.
465 U.S. 770 (Supreme Court, 1984)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Reves v. Ernst & Young
494 U.S. 56 (Supreme Court, 1990)
Stoiber v. Securities & Exchange Commission
161 F.3d 745 (D.C. Circuit, 1998)
Newsome v. Gallacher
722 F.3d 1257 (Tenth Circuit, 2013)
Bryant v. Smith Interior Design Group, Inc.
310 S.W.3d 227 (Supreme Court of Missouri, 2010)
Premium Financing Specialists, Inc. v. Hullin
90 S.W.3d 110 (Missouri Court of Appeals, 2002)
Grothe v. Helterbrand
946 S.W.2d 301 (Missouri Court of Appeals, 1997)
Covia v. Robinson
507 N.W.2d 411 (Supreme Court of Iowa, 1993)
State v. Burkinshaw
2010 UT App 245 (Court of Appeals of Utah, 2010)
Cavers v. HOUSTON MCLANE CO., INC.
2008 ME 164 (Supreme Judicial Court of Maine, 2008)
Moses v. Carnahan
186 S.W.3d 889 (Missouri Court of Appeals, 2006)
Bulldog Investors General Partnership v. Secretary of the Commonwealth
929 N.E.2d 293 (Massachusetts Supreme Judicial Court, 2010)
Leewaye v. IND. CLAIM APPEALS OFFICE OF STATE
178 P.3d 1254 (Colorado Court of Appeals, 2007)
Roer v. Oxbridge Inc.
198 F. Supp. 2d 212 (E.D. New York, 2001)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Dennis R. Di Ricco; Golden Genesis, INC. d/b/a Nuplasma; Thomas F. Casey v. Missouri Commissioner of Securities, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dennis-r-di-ricco-golden-genesis-inc-dba-nuplasma-thomas-f-casey-v-moctapp-2024.